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http://dx.doi.org/10.1016/j.kjms.201Abstract Vascular calcification is recognized as a common complication in some patients,
such as chronic renal failure. The purpose of this study was to investigate the role of sodium
thiosulfate (STS) for the transdifferentiation of human aortic vascular smooth muscle cells
into osteoblast-like cells induced by high-level phosphate. All human aortic vascular smooth
muscle cells were divided into STS group 1 (treatment with STS) and STS group 2 (culture in a
medium containing a high level of phosphate). STS group 1 included a normal group, a high-
level phosphate group, and other subgroups based on treatment with different concentrations
of STS. Cells of STS group 2 were cultured in a medium containing a high level of phosphate
for 72 hours, and then divided into a high-phosphate control group and other subgroups based
on treatment with different concentrations of STS. The mRNA and protein expressions of bone
morphogenetic protein-2 (BMP-2), core binding factor a-1 (Cbfa-1), and matrix Gla protein
(MGP) were detected. Meanwhile, calcium concentration and alkaline phosphatase (ALP) acti-
vation were measured. In STS group 1, the mRNA levels of BMP-2 and Cbfa-1 were elevated
significantly in the high-level phosphate group compared with the normal group (p < 0.05).
However, both gene expressions were attenuated in the STS-treated groups (vs. normal
group, p < 0.05). MGP mRNA levels were reduced in the high-level phosphate group (vs.
normal group, p < 0.05). In the STS-treated groups, mRNA expression of MGP was elevated
compared to the high-level phosphate group (p < 0.05). In STS group 2, expression of MGP
was enhanced significantly (vs. high-phosphate control group, p < 0.05) with both BMP-2
and Cbfa-1 reducing in the STS-treated groups (vs. high-phosphate-control group,
p < 0.05). STS attenuates calcium concentration and ALP activation. It can reverse osteoblastephrology, West China Hospital, Sichuan University, Chengdu 610041, China.
.com (P. Fu).
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related factors.
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Vascular calcification, specifically arterial calcification, is
recognized as a common complication in patients with
chronic renal failure [1]. Coronary artery calcification is
detected in more than 50% of patients on hemodialysis,
and its presence is associated with all-cause and cardio-
vascular mortality [2e9]. A number of studies have sug-
gested that high-level phosphate plays a key role in the
occurrence and development of vascular calcification
[10e12]. Although the research on metabolism of calcium
and phosphate and vascular calcification has become a hot
topic, there is still no effective treatment for vascular
calcification.
Vascular calcification was previously considered to be a
result of passive precipitation of calcium and phosphate
ions. However, recent findings suggest that vascular calci-
fication is an actively regulated process, which is induced
via several interlinked mechanisms in which phosphate
plays a key role in calcification [13,14]. This process is
characterized mainly by osteoblastic differentiation of
vascular smooth muscle cells (SMCs) and dysregulation of
endogenous calcification inhibitors [10,12].
Sodium thiosulfate (STS) is a chelating and reducing
agent. It has been used for the treatment of cyanide
poisoning in humans for more than 100 years [15].
Recently, Pasch et al. [16] provided convincing evidence
that STS prevents medial vascular calcification in uremic
rats. STS has been shown to delay the progression of cor-
onary artery calcification in patients on hemodialysis [17].
Although these results provide some scientific and clinic
evidence favoring the use of thiosulfate, the mechanism of
action is uncertain and needs to be clarified. It is hypoth-
esized that the removal of calcium from precipitated
minerals, thereby decreasing the calcification burden, and
enhancement of the urinary calcium loss may contribute to
the therapeutic effect of STS on calcification. However,
whether STS modulates calcification-related factors in
reducing phosphate-mediated vascular mineralization re-
mains unclear. The present study aimed at investigating
the effects of STS on high-level phosphate-induced osteo-
blastic differentiation of human aortic vascular smooth
muscle cells (HASMCs).Materials and methods
Reagents
HASMCs (6110) were purchased from ScienCell (Carlsbad,
CA, USA). Smooth muscle cell medium (SMCM) was obtained
from Yu Hengfeng Company (Beijing, China) and b-glycer-
ophosphate from Rego Company (Shanghai, China).Polyclonal antibodies of Cbfa-1, bone morphogenetic
protein-2 (BMP-2), and matrix Gla protein (MGP) were
purchased from Boster Company (Wuhan, China) and sec-
ondary antibodies from Zhongshan Company (Beijing,
China). Trizol reagent was obtained from Gibco (Tulsa, OK,
USA). RNA was reversely transcribed by using ReverTraAce
kit (Toyobo, Osaka, Japan). Bicinchoninic acid was pur-
chased from Beyotime Company (Haimen, Jiangsu, China).
Unless otherwise mentioned, all other analytical reagents
were purchased domestically.
Cell culture
HASMCs were cultured in an SMCM at 37C in a humidified
atmosphere containing 5% CO2. All cells were divided into
STS group 1 and STS group 2. STS group 1 was further
divided into a normal group, a high-level phosphate group,
and STS1000, STS2000, and STS3000 groups (treatment with
STS 1000 mg/mL, 2000 mg/mL, and 3000 mg/mL, respec-
tively). Cells of STS group 2 were cultured in a medium
containing a high level of phosphate for 72 hours and then
divided into a high-phosphate control, an STS-low, an STS-
middle, and an STS-high group.
mRNA analysis of BMP-2, Cbfa-1, and MGP by real-
time PCR
Primers were designed based on the published gene
sequence from Genbank (National Center for Biotechnology
Information, Bethesda, MD, USA). Primer sequences of BMP-
2 were as follows: 50-CGGTCTCCTAAAGGTCGACCAT-30
(forward primer) and 50-CGAACTTCCTGCGGCCCAGCT-30
(reverse primer). The PCR product size was 120 bp. Primer
sequences of Cbfa-1 were as follows: 50-GCGCATTTCA-
GATGATGACACT-30 (forward primer) and 50-CAGTTCTGAAG-
CACCTGCCT-30 (reverse primer). The PCR product size
was 91 bp. Primer sequences of MGP were as follows: 50-
GAATCACATGAAAGCATGG-30 (forward primer) and 50-
TCGCAAAGTCTGTAGTCAT-30 (reverse primer). The PCR
product size was 179 bp. Primer sequences of GAPDH
as the internal control were 50-CCTCAAGATCATCAGCAAT-30
(forward primer) and 50-CCATCCACAGTCTTCTGGGT-30
(reverse primer). The PCR product size was 141 bp. Total
RNA was extracted and analyzed using an ultraviolet spec-
trophotometer and by electrophoresis. Real-time PCR was
performed using Bio-Rad iCycler and iQ Real-Time PCR sys-
tems (Veenendaal, The Netherlands). Genes were amplified
by 40 cycles. Each cycle consisted of denaturation at 94C
for 5 minutes; annealing at 59C (for BMP-2), 55C (for Cbfa-
1), or 57C (for MGP) for 30 seconds; and extension at 72C
for 30 seconds. The PCR products were subjected to elec-
trophoresis and scanned. The cycle threshold (ct) value is
defined as the point at which the fluorescence generated
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Ct value of each sample was calculated using the
following formula: DCt Z Ct(sample)Ct(internal stan-
dard); DDCt Z DCtDCt(control). The mRNA level was
compared by calculating the values of 2DDct.Detection of BMP-2, Cbfa-1, and MGP protein by
Western blot
Total protein was extracted and was subjected to elec-
trophoresis. The membrane was blocked with 5% milk in
phosphate buffered saline (PBS) for 1e2 hours at room
temperature. Then the membrane was immunoblotted with
primary antibodies (1:400) to BMP-2, Cbfa-1, or MGP, and
incubated overnight at 4C. After incubation, the blot was
washed three times with TBST and immunoblotted with the
secondary antibody (1:20,000) for 1 hour at room temper-
ature. The blot was exposed under chemiluminescence and
analyzed by Quantity One software (version 4.2.2, Bio-Rad
Laboratories, Hercules, CA, USA). The optical density of
BMP-2 and Cbfa-1 was normalized to the optical density of
b-actin.Induction of transdifferentiation
HASMCs were routinely cultured in an SMCM. Cells were
treated with 10 mmol/L of b-glycerophosphate to induce
transdifferentiation. For the time-course experiment, the
1st day of culture in a medium with b-glycerophosphate was
defined as Day 0.Detection of calcium concentration
Calcium concentration was measured by a colorimetric
method using methyl thymol blue. After treatment with
STS, the cells were washed with hydrochloric acid for 24
hours. Then the supernatant was collected for the estima-
tion of calcium content.Alkaline phosphatase activation analysis
After treatment with STS, the cells were washed twice
with precooled PBS; next, the cells were collected
and total protein was extracted. After centrifugation
at 3500 rpm for 15 minutes, the supernatant was
collected for the detection of alkaline phosphatase (ALP)
activation.Figure 1. Changes in mRNA relative expressions of MGP,
BMP-2, and Cbfa-1 in STS group 1. * p < 0.05, versus normal
group. D p < 0.05, versus high-level phosphate group.
BMP2Z bone morphogenetic protein-2; Cbfa-1Z core binding
factor a-1; HP Z high-level phosphate group; MGP Z matrix
Gla protein; STS Z sodium thiosulfate.Statistical analysis
Data were presented as mean  standard deviation. The
significance of differences between all groups was evalu-
ated using one-way analysis of variance with a post hoc
StudenteNewmaneKeuls multiple comparisons test. Least
significance difference (LSD) was used to compare between
the two groups. Statistical analyses were performed using
SPSS 13.0 (SPSS Inc., Chicago, IL, USA), and p < 0.05 was
considered to be statistically significant.Results
mRNA expressions of BMP-2, Cbfa-1, and MGP
The mRNA expressions of BMP-2, Cbfa-1, and MGP were
calculated using the formula of 2DDCt. In STS group 1,
mRNA expressions of BMP-2 and Cbfa-1 on Day 2 were
significantly elevated in the high-level phosphate group
compared to that in the normal group (p < 0.05). How-
ever, both gene expressions were attenuated in the STS-
treated groups, including STS1000, STS2000, and STS3000
groups (vs. high-level phosphate group, p < 0.05). The
mRNA level of MGP was reduced in the high-level phos-
phate group (vs. normal group, p < 0.05). By contrast,
mRNA expression of MGP was elevated in the STS-treated
groups compared to that in the high-level phosphate
group (p < 0.05). These findings suggest that a high level
of phosphate can induce the transdifferentiation of
HASMCs into osteoblast-like cells by upregulating the ex-
pressions of BMP-2 and Cbfa-1, while downregulating MGP
expression. However, STS can inhibit such trans-
differentiation of HASMCs by downregulating the expres-
sions of BMP-2 and Cbfa-1 mRNA, while upregulating MGP
mRNA expression (Fig. 1).
In STS group 2, the expression of MGP was enhanced
significantly (vs. high-level phosphate control group,
p < 0.05) whereas that of BMP-2 and Cbfa-1 was decreased
in the STS-treated groups (vs. high-level phosphate control
group, p < 0.05). These findings revealed that STS can
inhibit the expressions of BMP-2 and Cbfa-1 mRNA while
upregulating MGP mRNA expression of HASMCs (Fig. 2).
Western blot analysis of BMP-2, Cbfa-1, and MGP
In STS group 1, expressions of BMP-2 and Cbfa-1 on Day 3
were elevated significantly in the high-level phosphate
group compared to that in the normal group (p < 0.05).
However, both protein expressions were attenuated in the
STS-treated groups, including STS1000, STS2000, and
STS3000 groups (vs. normal group, p < 0.05). MGP
expression was inhibited in the high-level phosphate
group (vs. normal group, p < 0.05), whereas it was
Figure 2. Changes in mRNA relative expressions of MGP,
BMP-2, and Cbfa-1 in STS group 2. D p < 0.05, versus high-level
phosphate control group. BMP2 Z bone morphogenetic
protein-2; Cbfa-1 Z core binding factor a-1; HP Z high-level
phosphate group; MGP Z matrix Gla protein; STS Z sodium
thiosulfate.
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suggest that a high level of phosphate can upregulate the
expressions of BMP-2 and Cbfa-1 while downregulating MGP
expression. However, STS can reverse these processes
(Fig. 3A and B).
In STS group 2, MGP expression on Day 3 was enhanced
significantly (vs. high-level phosphate control group,
p < 0.05) along with reductions of BMP-2 and Cbfa-1 in the
STS-treated groups (vs. high-level phosphate control group,
p < 0.05). These findings suggest that STS can reverse
mineralization by modulating the expressions of BMP-2,
Cbfa-1, and MGP (Fig. 4).Figure 3. Expressions of b-actin, MGP, BMP-2, and Cbfa-1 in STS g
level phosphate group. BMP2 Z bone morphogenetic protein-2; C
group; MGP Z matrix Gla protein; STS Z sodium thiosulfate.Attenuation of calcium concentration and ALP
activation by STS
As shown in Fig. 5A and B, in STS group 2, calcium con-
centration and ALP activation on Day 3 were attenuated
significantly after STS treatment (vs. high-level phosphate
control group, p < 0.05).
Discussion
In vitro studies showed that both bovine and human
vascular calcification can be induced in the presence of b-
glycerophosphate. A high extracellular phosphate concen-
tration leads to osteogenic differentiation of vascular SMCs
and mineralization of the collagenous extracellular matrix
produced by these differentiated cells [12,18e20]. The
increase of phosphate concentration in vascular smooth
muscle cells results in the downregulation of smooth
muscle-specific genes and upregulation of Cbfa-1, a central
transcription factor involved in osteoblast and chondrocyte
differentiation. An increase in the expression and activity
of the transcription factor Cbfa-1 characterizes osteogenic
phenotypic transition from SMCs [12]. Similar osteogenic
differentiation of vascular SMCs has also been observed in
human and animal models of vascular calcification. In the
present study, we found that the expressions of osteoblast
markers, including BMP-2 and Cbfa-1, were upregulated in
HASMCs whereas the calcification inhibitor, MGP, was
downregulated when cultured in a medium with a highroup 1. * p < 0.05, versus normal group. D p < 0.05, versus high-
bfa-1 Z core binding factor a-1; HP Z high-level phosphate
Figure 4. Expressions of b-actin, MGP, BMP-2, and Cbfa-1 in STS group 2. D p < 0.05, versus high-level phosphate control group.
BMP2 Z bone morphogenetic protein-2; Cbfa-1 Z core binding factor a-1; HP Z high-level phosphate group; HPC Z high-level
phosphate control group; MGP Z matrix Gla protein; STS Z sodium thiosulfate.
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demonstrated for the first time that STS downregulates
BMP-2 and Cbfa-1 induced by high-level phosphate. In
addition, STS can also upregulate the expression of MGP, a
calcification inhibitor, under high phosphate condition.
Accumulating evidence showed that BMP-2/Cbfa-1
signaling pathway plays a pivotal role in the process of
vascular calcification. BMP-2 can induce the expression of
Cbfa-1, and these two factors exert synergistic effects on
vascular calcification. BMP-2, a member of TGF superfamily,
is essential to the differentiation and proliferation of osteo-
blast and chondrocytes. The BMP-2-mediated in vitro differ-
entiation reduces the expressions of SMC-specific markers.
Moreover, exogenous BMP-2 can enhance calcium deposition
in bovine vessel cells. The core binding factor Cbfa-1 plays an
important role in the course of bone formation, differentia-
tion of multipotent mesenchymal stem cells to osteoblast,
osteoblastic differentiation, and osteogenic cellsmatrix gene
expression; it has been recognized to be the earliest andmost
specific osteoblast marker. Our previous findings suggest that
high-level glucose might evoke calcification of vascular
smooth muscle cells by inducing osteoblastic differentiation
and intracellular calcium deposition via the BMP-2/Cbfa-1
pathway in HASMCs in vitro [20]. The core binding factor
Cbfa-1 has been reported to be present in the vascular
calcified lesions of hemodialysis patients and non-
hemodialysis Chroinc Kidney Disease (CKD) patients [21,22].
Extracellular BMP signaling pathways are modulated by
transient inhibitors. These soluble inhibitors are tissue spe-
cific. A combination of soluble BMP inhibitors with BMP can
block the binding of BMP with its ligands.Figure 5. STS attenuates calcium concentration and ALP activa
ALP Z alkaline phosphatase; HPC Z high-level phosphate controlMGP is a highly potent inhibitor of cartilage and vascular
calcification. It is expressed mainly in cartilage and car-
diovascular tissues. The MGP knockout mouse developed
extensive aortic calcification spontaneously, and died at
6e8 weeks of age as a result of aortic rupture and subse-
quent internal hemorrhage [23]. This inhibitory effect of
MGP has partly been attributed to its capacity to bind and
inhibit BMP-2, a major regulator of Runx2/Cbfa-1 expres-
sion and a potent osteoinductive factor. MGP also abolishes
BMP2 receptor binding and phosphorylation of Smad1,
acting as an inhibitor of BMP2-dependent activation of
Smads, critical cofactors that are involved in Runx2/Cbfa-
1-dependent osteochondrogenic differentiation [24].
Sweatt et al. [25] showed that MGP binds to and inactivates
BMP-2, a promineralization factor. MGP is considered to be
a key inhibitor of BMP signaling pathways [26]. Trans-
differentiation of aortic SMCs into osteoblast-like cells is
observed in MGP-null mice in the presence of BMP. In
atherosclerosis and Monckeberg’s arteriosclerosis, MGP
expression is found to be downregulated even prior to
vascular calcification. Therefore, deficiency of BMP in-
hibitors such as MGP may contribute to the development of
vascular mineralization.
STS has been prescribed for the treatment of cyanide
toxicity for over a century. It has also been used for the
prevention of cisplatin-induced side effects. Cicone et al.
[27] first reported the application of STS in treating calci-
phylaxis. Further study also showed that STS can delay the
progression of vascular calcification successfully in hemo-
dialysis patients [17]. Some researchers demonstrated that
STS probably latches onto calcium to form calciumtion. * p < 0.05, versus high-level phosphate control group.
group; STS Z sodium thiosulfate.
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excreted easily [16,28]. Moreover, another document
showed that STS may induce pH reduction, followed by
consequent increases in calcium excretion and negative
calcium balance [16,29]. Finally, STS is a strong antioxidant
that can ameliorate oxidative insults in endothelial cells
[16]. However, it is unclear whether STS can affect the
transdifferentiation of HASMCs or modulate calcification-
related factors in reducing phosphate-mediated vascular
mineralization.
In the present study, in STS group 1, we found that the
expressions of BMP-2 and Cbfa-1 were elevated significantly
in the high-level phosphate group compared to that in the
normal control group. However, both expressions were
attenuated in the STS-treated groups. By contrast, MGP
expression was increased notably in the STS-treated groups
compared to that in the group treated with high-level
phosphate. These findings suggest that STS can inhibit the
transdifferentiation of HASMCs into osteoblast-like cells by
downregulating the expressions of BMP-2 and Cbfa-1 while
upregulating MGP expression mediated by phosphate. In
STS group 2, MGP expression was enhanced significantly,
whereas that of both BMP-2 and Cbfa-1 was reduced in the
STS-treated groups. These results indicate that STS can
inhibit the expressions of BMP-2 and Cbfa-1 while upregu-
lating MGP expression of HASMCs. It is likely that STS can
enhance the expression of MGP, and therefore inhibits the
BMP2/Cbfa-1 signaling pathways and subsequent vascular
mineralization. Meanwhile, in the present study, STS could
attenuate calcium concentration and ALP activation
(Fig. 5). However, more studies are warranted to elucidate
the underlying mechanisms.
In conclusion, high-level phosphate can induce the
transdifferentiation of HASMCs into osteoblast-like cells
by enhancing the expressions of BMP-2 and Cbfa-1. Our
study demonstrates for the first time that STS down-
regulates the expressions of BMP-2 and Cbfa-1 induced by
high-level phosphate. In addition, STS can also upregulate
the expression of MGP in a high-phosphate condition.
These findings suggest that STS can reverse mineralization
by modulating the expression of calcification-related
factors. However, more studies are warranted to further
elucidate the underlying mechanisms. Our findings offer a
novel mechanism for explaining metastatic calcification
and may lead to the development of new therapeutics
aimed at reducing or preventing ectopic calcification.References
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